Abbisko Cayman Ltd
HKEX:2256
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abbisko Cayman Ltd
Retained Earnings
Abbisko Cayman Ltd
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abbisko Cayman Ltd
HKEX:2256
|
Retained Earnings
-¥3.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Retained Earnings
-¥61.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Retained Earnings
¥19.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Retained Earnings
-¥3.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Retained Earnings
¥9.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Retained Earnings
¥2.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbisko Cayman Ltd
Glance View
Abbisko Cayman Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
See Also
What is Abbisko Cayman Ltd's Retained Earnings?
Retained Earnings
-3.8B
CNY
Based on the financial report for Dec 31, 2025, Abbisko Cayman Ltd's Retained Earnings amounts to -3.8B CNY.
What is Abbisko Cayman Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-27%
Over the last year, the Retained Earnings growth was 0%. The average annual Retained Earnings growth rates for Abbisko Cayman Ltd have been -4% over the past three years , -27% over the past five years .
